Company intelligence / Profile preview
Vitro Biopharma
Denver, Colorado, United Statesvitrobiopharma.com ↗
- Ownership
- Private
- Employees
- ~17
- Development stage
- Other
01
Overview
Vitro Biopharma’s lead program focuses on AlloRx Stem Cell therapy derived from Wharton’s jelly MSCs. The company has authorization to conduct two FDA IND trials in the US for PTHS and Long COVID/PASC. Over 300 subjects have been treated with their product in international studies primarily conducted by third parties. Clinical trial initiation was targeted for late 2022 or early 2023 pending funding.[1][3]
- Therapeutic areas
- ImmunologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Wharton's jelly-derived mesenchymal stem cells (MSCs)allogeneic cell therapy[1][3][6]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Not specifically listed; company mentions international clinical collaborations with third-party investigators [2].
Beyond the preview
Go deeper on Vitro Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vitro Biopharma.